Travere Therapeutics Inc [TVTX] stock is trading at $36.47, up 1.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TVTX shares have gain 8.16% over the last week, with a monthly amount glided 39.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 31, 2025, when Citigroup reiterated its Buy rating and also boosted its price target to $48 from $34. On June 11, 2025, Citigroup reiterated its Buy rating and revised its price target to $32 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Wells Fargo upgraded its rating to a Overweight and raised its price target to $27 on October 21, 2024. In a note dated September 09, 2024, Guggenheim upgraded an Buy rating on this stock but restated the target price of $25.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $12.91 and $36.76 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $36.47 at the most recent close of the market. An investor can expect a potential drop of -4.03% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 435.83M for the trailing twelve months, which represents a growth of 162.11%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.21%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -1.79 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of4.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.63 points at the first support level, and at 34.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.95, and for the 2nd resistance point, it is at 37.42.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 2.75. Further, the Quick Ratio stands at 2.71, while the Cash Ratio is 0.82. Considering the valuation of this stock, the price to sales ratio is 7.49, the price to book ratio is 44.35.
Transactions by insiders
Recent insider trading involved Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER, that happened on Nov 04 ’25 when 67115.0 shares were sold. Officer, SANDRA CALVIN completed a deal on Nov 04 ’25 to buy 67115.0 shares. Meanwhile, Director Coughlin Timothy sold 18000.0 shares on Oct 31 ’25.
